IRIS
PASSALACQUA, GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 58.941
AS - Asia 56
SA - Sud America 43
NA - Nord America 4
AF - Africa 2
Totale 59.046
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 58.935
BR - Brasile 39
VN - Vietnam 24
CN - Cina 20
SG - Singapore 6
US - Stati Uniti d'America 4
AR - Argentina 3
DZ - Algeria 2
IQ - Iraq 2
AT - Austria 1
BA - Bosnia-Erzegovina 1
EC - Ecuador 1
FI - Finlandia 1
FR - Francia 1
ID - Indonesia 1
JO - Giordania 1
JP - Giappone 1
RU - Federazione Russa 1
UA - Ucraina 1
UZ - Uzbekistan 1
Totale 59.046
Salva come PNG Salva come JPEG
Città #
Genova 41.035
Genoa 10.346
Rapallo 4.496
Vado Ligure 2.986
Bordighera 71
Ho Chi Minh City 10
Beijing 5
Singapore 4
Hanoi 3
Araraquara 2
Biên Hòa 2
Campinas 2
Long An 2
Payne 2
São Paulo 2
Amman 1
Araçatuba 1
Ashburn 1
Boardman 1
Brasília 1
Buenos Aires 1
Camaçari 1
Can Tho 1
Contagem 1
Da Nang 1
Dourados 1
Duque de Caxias 1
Erbil 1
Erechim 1
Guarapuava 1
Guayaquil 1
Haiphong 1
Indaiatuba 1
Irecê 1
Jacareí 1
Jakarta 1
Jaraguá do Sul 1
Joinville 1
Juazeiro do Norte 1
Kryvyi Rih 1
Maragogi 1
Milan 1
Ninh Bình 1
Nova Brasilândia d'Oeste 1
Nova Olímpia 1
Paris 1
Parobé 1
Paulo Afonso 1
Paulínia 1
Porto Alegre 1
Queimada Nova 1
Quảng Ngãi 1
Ribeirão Preto 1
Rio das Ostras 1
Rio de Janeiro 1
San Miguel de Tucumán 1
Santo Ângelo 1
Sarajevo 1
Smolensk 1
Suzano 1
São Gonçalo 1
São Jorge do Ivaí 1
Taquaral de Goiás 1
Tashkent 1
Tokyo 1
Tây Ninh 1
Valinhos 1
Vargem Grande Paulista 1
Varginha 1
Vienna 1
Totale 59.023
Salva come PNG Salva come JPEG
Nome #
Clinical characteristics, management and in-hospital mortality of patients with COVID-19 In Genoa, Italy 258
Immunoterapia specifica: una possibilità di gestione del rischio professionale da allergia al veleno di imenotteri 216
Cetirizine reduces inflammatory cell recruitment and ICAM-1 (or CD54) expression on conjunctival epithelium in both early and late phase reactions after allergen-specific challenge. 192
A Review of the Evidence from Comparative Studies of Levocetirizine and Desloratadine for the Symptoms of Allergic Rhinitis 181
Levocetirizine in persistent allergic rhinitis and asthma: effects on symptoms, quality of life and inflammatory parameters. 181
NK cells from malignant pleural effusions are not anergic but produce cytokines and display strong antitumor activity on short-term IL-2 activation. 179
Adhesion molecules in allergy. 177
A critical evaluation of Anti-IL-13 and Anti-IL-4 strategies in severe asthma 177
A three-year double-blind placebo-controlled study with specific oral immunotherapy to Dermatophagoides: evidence of safety and efficacy in paediatric patients. 175
Molecular phenotyping and biomarker development: Are we on our way towards targeted therapy for severe asthma? 170
Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma 166
Sublingual immunotherapy abrogates seasonal bronchial hyperresponsiveness in children with Parietaria-induced respiratory allergy: a randomized controlled trial. 165
A double-blind, placebo-controlled study on the diagnostic accuracy of an electrodermal test in allergic subjects. 163
Mepolizumab in the management of severe eosinophilic asthma in adults: Current evidence and practical experience 162
A survey of clinical features of allergic rhinitis in adults. 158
Functionally relevant decreases in activatory receptor expression on NK cells are associated with pulmonary tuberculosis in vivo and persist after successful treatment. 156
Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life 156
The additional values of microarray allergen assay in the management of polysensitized patients with respiratory allergy. 155
Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes in healthy human beings. 154
Nasal immunotherapy to Parietaria: evidence of reduction of local allergic inflammation. 153
Efficacy of mometasone furoate nasal spray in the treatment of allergic rhinitis. Meta-analysis of randomized, double-blind, placebo-controlled, clinical trials. 153
A new protocol for specific oral tolerance induction in children with IgE-mediated cow's milk allergy. 153
Prevalence and prognostic value of cardiac troponin in elderly patients hospitalized for COVID-19 153
Fibrous invasive (Riedel's) thyroiditis with critical response to steroid treatment. 152
Local Side Effects of Sublingual and Oral Immunotherapy 152
Catching allergy by a simple questionnaire 151
Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. 149
Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. 149
Personalized medicine in allergy 149
Allergy and the bone: unexpected relationships. 148
CD4(+)IL-13(+) cells in peripheral blood well correlates with the severity of atopic dermatitis in children. 147
Venom immunotherapy in patients with clonal mast cell disorders: efficacy, safety, and practical considerations. 147
Anti-IL-5 and IL-5Ra: Efficacy and safety of new therapeutic strategies in severe uncontrolled asthma 146
Efficacy of Buffered Hypertonic Saline Nasal Irrigation for Nasal Symptoms in Children with Seasonal Allergic Rhinitis: A Randomized Controlled Trial 146
Aerobiologic diagnosis of brassicaceae-induced asthma. 145
Latex-jujube cross-reactivity: case report and immunological study. 145
Basi Patogenetiche ed anatomopatologiche della flogosi allergica nell’asma bronchiale 144
Current insights in allergen immunotherapy 144
Focus on cat allergen (Fel d 1): immunological and aerodynamic characteristics, modality of airway sensitization and avoidance strategies. 144
Continuous versus on demand treatment with cetirizine for allergic rhinitis. 143
Inhaled Corticosteroids Safety and Adverse Effects in Patients with Asthma 143
A critical appraisal on AIT in childhood asthma 143
When allergic rhinitis is not only allergic. 142
A WAO — ARIA — GA2LEN consensus document on molecular-based allergy diagnosis (PAMD@): Update 2020 140
How adherent to sublingual immunotherapy prescriptions are patients? The manufacturers' viewpoint. 139
The role of basophil activation test in special populations with mastocytosis and reactions to hymenoptera sting. 139
A prospective italian survey on the safety of subcutaneous immunotherapy for respiratory allergy. 139
Important research questions in allergy and related diseases: nonallergic rhinitis: a GA2LEN paper 138
The natural history of respiratory allergy: a follow-up study of 99 patients up to 10 years 138
Sublingual immunotherapy: other indications. 138
When to stop biologicals. Severe asthma exacerbation after mepolizumab discontinuation 138
Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. 137
Sublingual and oral immunotherapy. 137
The functional connection between oral allergy syndrome and united airways disease assessed by oral challenge. 137
The safety of monoclonal antibodies in asthma 137
Nasal cytology: Methodology with application to clinical practice and research 137
Long-term follow-up of nasal immunotherapy to Parietaria: clinical and local immunological effects. 136
An update on the asthma-rhinitis link. 136
Evidence of desloratadine syrup efficacy and tolerability in children with pollen-induced allergic rhinitis. 136
Sublingual immunotherapy. 136
Molecular diagnosis and precision medicine in allergy management 136
Manifesto on small airway involvement and management in asthma and chronic obstructive pulmonary disease: an Interasma (Global Asthma Association - GAA) and World Allergy Organization (WAO) document endorsed by Allergic Rhinitis and its Impact on Asthma (ARIA) and Global Allergy and Asthma European Network (GA2LEN) 136
Umeclidinium for the treatment of uncontrolled asthma 136
Serum cytotoxic T lymphocyte-associated antigen 4 in hymenoptera venom allergy and its modulation by specific immunotherapy 136
Levocetirizine in persistent allergic rhinitis: continuous or on-demand use? A pilot study. 135
The asthma-rhinitis association: between the clinical hypothesis and the scientific theory. 135
Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. 135
The classification of allergic rhinitis and its cytological correlate. 135
Clinical characteristics, management and in-hospital mortality of patients with coronavirus disease 2019 in Genoa, Italy 134
Safety of sublingual immunotherapy with a monomeric allergoid in very young children. 133
New perspectives in the treatment of allergic rhinitis and asthma in children 133
New insights in sublingual immunotherapy. 133
Allergen-specific nasal challenge: response kinetics of clinical and inflammatory events to rechallenge. 133
Will sublingual immunotherapy offer benefit for asthma? 133
Daily allergic multimorbidity in rhinitis using mobile technology: A novel concept of the MASK study 133
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision 133
MK-8237: a house dust mite vaccine for treating allergic rhinitis, asthma and atopic dermatitis 133
Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. 133
Continuous antihistamine treatment controls allergic inflammation and reduces respiratory morbidity in children with mite allergy. 132
Allergic rhinitis and its impact on asthma update: allergen immunotherapy. 132
Exercise-induced anaphylaxis to grape. 132
Prevalence of allergy to Cypress. 132
Antihistamines in atopic dermatitis. 132
Appropriateness in allergic respiratory diseases health care in Italy: Definitions and organizational aspects 132
Targeting Interleukin-5 or Interleukin-5Rα: Safety Considerations 132
Adherence to sublingual immunotherapy in preschool children. 132
Efficacy of mepolizumab in patients with previous omalizumab treatment failure: Real-life observation 132
United airways disease: therapeutic aspects 131
Randomized double-blind controlled study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due to mites 131
Loratadine treatment of rhinitis due to pollen allergy reduces epithelial ICAM-1 expression. 131
Sublingual immunotherapy for allergic rhinitis and conjunctivitis. 131
Anaphylactic Reactions After Discontinuation of Hymenoptera Venom Immunotherapy: A Clonal Mast Cell Disorder Should Be Suspected 131
The path to personalized medicine in asthma 131
Allergenius, an expert system for the interpretation of allergen microarray results 131
Comparison of the effects in the nose and skin of a single dose of desloratadine and levocetirizine over 24 hours. 130
Sublingual immunotherapy in the treatment of adult allergic rhinitis patients. 130
Sublingual immunotherapy for allergic rhinitis: an update. 130
Lower airway inflammation before and after house dust mite nasal challenge: An age and allergen exposure-related phenomenon. 129
Dermatological powder as hidden cause of occupational allergy due to casein: a case report. 129
Efficacy of sublingual immunotherapy. 129
Totale 14.517
Salva come PNG Salva come JPEG
Categoria #
all - tutte 192.025
article - articoli 191.019
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.006
Totale 384.050
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213.131 0 0 0 389 227 323 216 419 358 470 273 456
2021/20226.596 152 387 560 940 117 560 551 1.378 276 571 310 794
2022/20235.473 598 221 30 477 836 1.112 52 508 1.078 96 388 77
2023/20242.361 177 419 52 195 233 362 122 106 129 47 162 357
2024/20256.939 101 700 275 440 1.060 682 659 861 267 382 575 937
2025/20263.314 1.237 385 854 838 0 0 0 0 0 0 0 0
Totale 59.791